Citations

Clear

1012 citation(s) found for "Zhao, C".

Humanized tau and amyloid-β deposition accelerate tau propagation, neuronal cell loss and neurophysiological dysfunction in novel mouse models of primary age-related tauopathy and Alzheimer’s disease
Hagita-Tatsumoto, Ayaka, Gibbs, Brendan J. , Ray, Nibedita Basu, Ellison, J. W, Longtree‐Preciado, Alejandro, Radhakishun, Stephanie, Zhao, Na, Saito, Takashi, Ikezu, Seiko , Ikezu, Tsuneya , Zhao, Na , Zhao, Na , Ikezu, Tsuneya , Ravula, Arun Reddy , Gibbs, Brendan J. , Qiao, Wenhui

Mayo Clinic

No container title available | February 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.23.707081 | PMID 42124584 Get It

Abstract In Alzheimer’s disease (AD), tau pathology arises in entorhinal cortex layer II (ECII) and advances through defined hippocampal circuits to CA1 and connected neocortical regions, yet the determinants of this hierarchical spread remain unclear. We previously established a circuit-defined propagation model by expressing Cre-inducible human P301L 2N4R tau selectively in Wolframin-1 (Wfs1) + ECII neurons using AAV-FLEX-Tau P301L in Wfs1-Cre mice. Here, to test how amyloid-β (Aβ) and human tau background shape propagation, we generated human MAPT knock-in Wfs1 mice and APP NL-G-F / MAPT double knock-in Wfs1 mice (T-Wfs1 and AT-Wfs1) and induced ECII-restricted Tau P301L expression. Three months after injection, phosphorylated or misfolded tau-positive neurons were enriched in proximal CA1 in Wfs1 and T-Wfs1 mice, resembling primary age-related tauopathy, whereas AT-Wfs1 mice showed preferential accumulation near the CA1/subiculum (Sub) boundary, consistent with an AD-like pattern. In T-Wfs1 and AT-Wfs1 mice, tau spread extended through Sub to neocortical regions, and phosphorylated tau accumulated predominantly in excitatory rather than inhibitory neurons. Electrophysiological analyses revealed increased spontaneous neuronal firing and impaired GABAergic transmission in the CA1/Sub boundary and neocortical areas in T-Wfs1 and AT-Wfs1 mice, indicative of impaired GABAergic input and enhanced neuronal excitability in these regions. Together, these data indicate that human MAPT and Aβ pathology shift the circuit topography of tau propagation and are associated with early network dysfunction, supporting a synergistic interaction that promotes AD-like spread and synaptic imbalance.
Improved Skeletal Dynamics in Adults Treated with Palopegteriparatide for Chronic Hypoparathyroidism: 214-Week Results from the Phase 2 PaTH Forward Trial
Rubin, M, Khan, A, Schwarz, Peter, Palermo, A, Cetani, F, Kohlmeier, L, Jain, R, Clarke, B, Zhao, C, Ominsky, M, Lai, B, Ukena, J, Sibley, C, Shu, A, Rejnmark, L, Tsourdi, Elena , Rubin, Mishaela R. , Palermo, Andrea , Cetani, Filomena , Kohlmeier, Lynn, Clarke, B.L. , Ominsky, Michael S. , Lai, B, Ukena, Jenny, Sibley, Christopher T. , Shu, Aimee D , Rejnmark, Lars

Mayo Clinic

Osteologie | February 24, 2026 | Volume: 35 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1815997 Get It

Med-VLM: Enhancing Medical Image Segmentation Accuracy Through Vision-Language Model
Zhao, Yihao, Zhong, Enhao, Yuan, Cuiyun, Li, Yang, Zhao, Man , Li, Chunxia, Hu, Jun, Liu, Wei, Liu, Chaoying

Mayo Clinic

2025 IEEE/CVF International Conference on Computer Vision Workshops (ICCVW) | February 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: 7342-7352

10.1109/iccvw69036.2025.00756 Get It

Deletion of the ncPRC1 Subunit RYBP Located at 3p13 Epigenetically Reprograms Primary Prostate Cancer
Ma, Jie, Wei, X F, Cui, Mingxuan , Zhang, Shufen , Huo, Yanfang, Wang, Jianxun, Wang, Liguo, Zhao, Jicheng, Cui, Mingxuan, Zhang, Shujie, Wei, Ting

Mayo Clinic

No container title available | February 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8711884/v1 Get It

Abstract Polycomb group (PcG) proteins form the Polycomb Repressive Complexes 1 and 2 (PRC1/2), which regulate gene expression through histone modifications. Their dysregulation is implicated in cancer. Genomic analysis of prostate cancer datasets revealed a striking divergence: PRC1 genes are frequently amplified in metastatic disease (SU2C), correlating with poor survival, higher tumor mutational burden (TMB), and enhanced androgen receptor (AR) signaling. In contrast, primary prostate cancer (PRAD) is characterized by recurrent deletion of the 3p13 locus, which harbors the gene for the non-canonical PRC1 subunit RYBP. Transcriptomic analysis indicated that RYBP loss derepresses gene expression, consistent with its role in transcriptional repression. Functionally, RYBP expression positively correlates with AR activity and negatively associates with neuroendocrine (NEPC) differentiation. Spatial and single-cell transcriptomics further show that RYBP is enriched in normal epithelial cells but downregulated in tumor cells. Besides, tumors with lower RYBP expression exhibit an immunosuppressive microenvironment, characterized by increased regulatory T cells. Collectively, these findings position RYBP deletion not only as a novel DNA-based biomarker for primary prostate cancer but also as a pivotal epigenetic deregulation event that coordinates oncogenic signaling and lineage plasticity.
Finite Element Modeling of the Scaphoid Shift Maneuver: Implications for Scapholunate Ligament injuries
Andreassen, Thor E. , Thoreson, Andrew R. , Parunyu, Vilai, An, Kai-Nan, Kakar, Sanjeev , Zhao, Kristin D. , Trentadue, Taylor P , Thoreson, Andrew R , An, Kai-Nan , Kakar, Sanjeev , Trentadue, Taylor P , Andreassen, Thor E , Trentadue, Taylor P. , Vilai, Parunyu , An, Kai‐Nan

Mayo Clinic

No container title available | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.17.705556 | PMID 41756899 Get It

Abstract Background Computational modeling is a tool being deployed for orthopaedic solutions but its use in the hand and wrist remains limited. This work used a model to simulate a clinically relevant provocative scaphoid shift maneuver (SSM) with different levels of scapholunate interosseous ligament (SLIL) injuries to observe the effect on different metrics. Methods A personalized model simulated the full SSM motion cycle from ulnar deviation with extension to radial deviation with flexion informed by the participant’s motion obtained from dynamic computed tomography. Models repeated the SSM under different levels of SLIL injury and reported changes in joint kinematics, contact mechanics, and ligament forces. Results The fully injured model increased scaphoid dorsal translation, flexion, and radial deviation compared to the intact condition and caused a subluxation of the scaphoid. Radioscaphoid contact areas were approximately 200% greater in the fully injured model compared with all others and the fully injured model was the only condition where contact force decreased across the motion cycle. Ligament forces in the intact condition were on average 33.0 N and 54.2 N for the volar and dorsal SLIL, respectively. Lastly, the long radiolunate, an extrinsic stabilizer, had forces that increased following SLIL injury. Conclusions Computational models can successfully recreate clinically observed behaviors of an SSM, including scaphoid subluxation, while providing new insights via quantification of contact mechanics and ligament forces. Contact mechanics metrics may be important for understanding the long-term progression of untreated SLIL injuries to osteoarthritis. Additionally, ligament force metrics may explain the progression of SLIL injuries from volar SLIL to dorsal SLIL and highlight the importance of repairing extrinsic stabilizers of the joint, due to increased force sharing following SLIL injury. This work provides a pathway to future studies investigating the effects of SLIL injury and repair, both acutely and chronically.
Abstract GS1-04: Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trial
Badve, S. S., Zhao, F., Tung, NM, O'Sullivan, C. C., Prat, A., Winer, E. P., Wright, J. L., Recht, A., Weiss, A. C., Tjoe, J. A., Feldman, S. M., Rocque, G. B., Smith, M., Unni, N., Sardesai, S., Modi, S., Irvin, W. J., Villagrassa, P., Battelli, Chiara, Krie, A. K., Bagegni, N. A., George, M. A., Telli, M. L., Borges, V. F., D’Abreo, Nina , Shah, P. D., Miller, K. D., Partridge, A. H., Carey, L. A., DeMichele, A. M., Wolff, A. C., ECOG-ACRIN, Badve, Sunil , Tung, Nadine , Gökmen‐Polar, Yesim , O’Sullivan, Ciara C. , Prat, Aleix , Wright, J. L., Recht, A., Weiss, A. C., Rocque, Gabrielle B. , Unni, N., Sardesai, Sagar , Tang, Shou-Ching , Irvin, William , Bagegni, Nusayba , Telli, M.L., Partridge, Ann H. , Carey, L., DeMichele, Angela , Wolff, Antonio C

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: GS1-04-GS1-04

10.1158/1557-3265.sabcs25-gs1-04 Get It

Abstract Background: The association of TILs with pathologic complete response (pCR) and survival in HER2+ breast cancer is not well established with several prior studies showing inconsistent results. In this secondary analysis of EA1181, we evaluated the association between stromal TILs (sTILs) and pCR rates. Methods: EA1181 (NCT04266249) enrolled patients (pts) with anatomic clinical stage II/III HER2+ breast cancer who preoperatively received 4 cycles of trastuzumab and pertuzumab with 12 weeks of paclitaxel or docetaxel q3w x 4 (THP), followed by surgery. sTILs density was assessed on full-face hematoxylin and eosin (H&E)-stained tumor biopsy sections. sTILs scores were analyzed per protocol as a continuous variable (every 10% increment) and as a categorical variable (<10% vs 10-60% vs >60% as per Denkert et al, 2018), and also with an exploratory 30% cutoff commonly used in TNBC. Cox proportional hazards models were used to examine the association between sTILs and pCR, adjusting for available baseline factors. The associations between sTILs (by category) and clinicopathologic characteristics were examined using Fishers’ exact test. Results: Among 2141 pts with HER2+ BC treated on EA1181, H&E slides were available for 1328 (62%). The study population evaluated for sTILs was comparable to the overall population. pCR rates were 44.5% overall, 64% for HER2+/ER- and 33% for HER2+/ER+ disease. sTILs distribution was: 623 (47%) <10%, 698 (52%) 10-60%, and 7 (0.5%) >60%, which led us to merge the latter two groups (705 [53%] had ≥10% sTILs). In univariable and multivariable analyses, increasing sTILs (as a continuous variable) were associated with increasing pCR rates in both HER2+/ER+ and HER2+/ER- disease (p<0.001; Table). sTILs analyzed as a categorical variable (<10% vs ≥10%) were significantly associated with pCR for all patients (combined) and for those with HER2+/ER+ disease. In exploratory analysis using a cutoff of <30% vs ≥30% sTILs, an association with pCR was also seen in univariable analysis for both HER2+/ER+ disease (p<0.001) and HER2+/ER- disease (p=0.045), though in multivariable analysis with clinical factors, sTILs >30% remained a significant predictor for pCR only in HER2+/ER+ disease. Additional exploratory analysis with other molecular biomarkers, intrinsic subtypes, and immune signatures will be presented. Conclusion: sTILs were associated with pCR after THP, further supporting the important role of immune mechanisms in HER2+ breast cancer, and highlighting a potentially robust predictive tool to assess pathologic response. Baseline sTILs could potentially inform the preoperative design of future trials of therapy optimalization. Association of baseline sTILs with recurrence free survival in EA1181 will be reported in the future. Citation Format: S. S. Badve, F. Zhao, N. Tung, Y. Gokmen-Polar, C. C. O'Sullivan, A. Prat, E. P. Winer, J. L. Wright, A. Recht, A. C. Weiss, J. A. Tjoe, S. M. Feldman, G. B. Rocque, M. Smith, N. Unni, S. Sardesai, S. Tang, S. Modi, W. J. Irvin, P. Villagrassa, C. Battelli, A. K. Krie, N. Bagegni, M. A. George, M. L. Telli, V. F. Borges, N. D’Abreo, P. Shah, K. D. Miller, A. H. Partridge, L. A. Carey, A. M. DeMichele, A. C. Wolff, ECOG-ACRIN.Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trial [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr GS1-04.
Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis optica model induced by subarachnoid AQP4-IgG
Qi, Fangfang, Lennon, Vanda A. , Zhao, Shunyi, Guo, Yong, Ding, Husheng, Liu, Caiyun, Bartley, Whitney M., Chen, Tingjun, Lucchinetti, Claudia F. , Wu, Long-jun, Wu, Long‐Jun , Guo, Yong , Wu, Long-Jun , Guo, Yong , Qi, Fangfang

Mayo Clinic

Journal of Clinical Investigation | February 10, 2026 | Volume: 136 | Issue: 7 | Pages: No page available

10.1172/jci199706 | PMID 41665955 Get It

Neutrophils and neutrophil extracellular traps (NETs) contribute to early neuromyelitis optica (NMO) histopathology initiated by IgG targeting astrocytic aquaporin-4 (AQP4) water channels. Yet, the mechanisms underlying neutrophil recruitment and their pathogenic roles in disease progression remain unclear. To investigate molecular-cellular events preceding classical complement cascade activation in a mouse NMO model, we continuously infused, via spinal subarachnoid route, a non-complement-activating mouse monoclonal AQP4-IgG. Parenchymal infiltration of netting neutrophils containing C5a ensued with microglial activation and motor impairment but no blood-brain barrier leakage. Motor impairment and neuronal dysfunction both reversed when AQP4-IgG infusion stopped. Two-photon microscopy and electron microscopy–based reconstructions revealed physical interaction of infiltrating neutrophils with microglia. Ablation of either peripheral neutrophils or microglia attenuated the motor deficit, highlighting their synergistic pathogenic roles. Of note, mice lacking complement receptor C5aR1 exhibited reduction in neutrophil infiltration, microglial lysosomal activation, neuronal lipid droplet burden, and motor impairment. Pharmacological inhibition of C5aR1 recapitulated this protection. Immunohistochemical analysis of an NMO patient’s spinal cord revealed disease-associated microglia surrounding motor neurons in nondestructive lesions. Our study identifies neutrophil-derived C5a signaling through microglial C5aR1 as a key early driver of reversible motor neuron dysfunction in the precytolytic phase of NMO.
Overview of an ongoing clinical trial on hand prostheses: Toward use of synergy-based prosthetic hands for activities of daily living by transradial amputees
Lopez, Cesar , Scrabeck, Tyson L., Catalano, Manuel G., Bicchi, Antonio , Fani, Simone , Jahanian, Omid, Catalano, Manuel G. , Zhao, Kristin D. , Santello, Marco

Mayo Clinic

IEEE Transactions on Biomedical Engineering | February 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.1109/tbme.2026.3662250 | PMID 41662545 Get It

A Purified Platelet-Derived Exosome Product for Chronic Wound Healing: A Novel Therapeutic Strategy and Next-Generation Delivery Platform
Wan, Rou , Nishimura, Ken , Zhao, Chunfeng, Moran, Steven L. , Zhao, Chunfeng , Zhao, Chunfeng , Behfar, Atta

Mayo Clinic

Pharmaceutics | February 9, 2026 | Volume: 18 | Issue: 2 | Pages: 222

10.3390/pharmaceutics18020222 | PMID 41754964 Get It

Chronic wounds remain a major unmet clinical challenge, often failing to progress to normal healing due to persistent inflammation, impaired angiogenesis, and cellular senescence. Exosomes have recently been investigated as promising acellular therapeutics capable of restoring intercellular communication and promoting tissue regeneration. Among these, the Purified Exosome Product (PEP) represents a next-generation, platelet-derived exosome formulation manufactured under Good Manufacturing Practice (GMP) conditions with high purity, stability, and reproducibility. This review summarizes the current advances in exosome-based chronic wound therapeutics and PEP delivery systems and their translational potentials. Incorporation of PEP into bioengineered carriers such as fibrin sealant, collagen scaffolds, and hyaluronic acid (HA) hydrogels enables localized and sustained exosome release, significantly prolonging therapeutic effects and improving regenerative outcomes. Fibrin-based PEP delivery achieved complete wound closure and functional skin regeneration in animal models, while collagen and HA-based systems showed promising results for injectable and dermatologic applications. Beyond its intrinsic healing effects, PEP may also serve as a nanocarrier for other drugs, offering a future direction in chronic wound management.
Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders
Zhang, Zhao, Somerville, Emma N. , Fang, Zih‐Hua , Liu, Lang, Asayesh, Farnaz , Ahmad, Jamil, Amiri, Saeid , Teferra, Meron, Dodet, P., Arnulf, Isabelle, Hu, Michele T.M., Desautels, A., Dauvilliers, Yves, Aktan-Süzgün, Merve , Stefani, A., Högl, Birgit, Gaig, Carles, Mayà, G., Iranzo, Alex, Serradell, Mònica , Valente, Mariarosaria, Dusek, P., Sommerauer, Michael , Röttgen, Sinah, Figorilli, M., Puligheddu, Monica, Mollenhauer, Brit, Trenkwalder, Claudia, Sixel-Doring, Friederike, Plazzi, G., Antelmi, E., Terzaghi, Michele, Fiamingo, Giuseppe , Ferini-Strambi, Luigi, Kulcsarova, Kristina, Bušková, J., Abril, Beatriz, Orso, B., Arnaldi, D., Boeve, Bradley F., Ju, Yo‐El S. , Ross, Owen A., Wu, Shih-Ying, Lee, Jonghun , Prilutsky, Daria, Blauwendraat, Cornelis, Leonard, Hampton, Postuma, Ronald B., Rouleau, Guy A., Gan-Or, Ziv, Arnulf, Isabelle , Hu, Michele T M , Desautels, Alex , Dauvilliers, Yves , Ibrahim, Abubaker , Stefani, Ambra , Högl, Birgit , Montini, Angelica , Maya, Gerard , Serradell, Monica , Gigli, Gian Luigi , Valente, Mariarosaria , Janes, Francesco , Sonka, Karel , Kemlink, David , Dušek, Petr , Figorilli, Michela , Puligheddu, Monica , Mollenhauer, Brit , Trenkwalder, Claudia , Sixel-Doring, Friederike , Plazzi, Giuseppe , Biscarini, Francesco , Antelmi, Elena , Cochen De Cock, Valérie , Terzaghi, Michele , Fiamingo, Giuseppe , Heidbreder, Anna , Ferini-Strambi, Luigi , Ostrozovicova, Miriam , Skorvanek, Matej , Kulcsarova, Kristina , Buskova, Jitka , Orso, Beatrice , Mattioli, Pietro , Arnaldi, Dario , Boeve, Brad , Ross, Owen A , Blauwendraat, Cornelis , Postuma, Ronald B , Rouleau, Guy Armand , Gan-Or, Ziv , Zhang, Zhao , Liu, Lang , Ahmad, Jamil, Teferra, Meron , Dodet, Pauline , Arnulf, Isabelle , Désautels, Alex , Dauvilliers, Yves , Ibrahim, Abubaker , Stefani, Ambra , Högl, Birgit , Gaig, Carles , Mayà, Gerard , Iranzo, Álex , Serradell, Mónica , Janes, Francesco , Bernardini, Andrea , Šonka, Karel , Dušek, Petr , Röttgen, Sinah , Figorilli, Michela , Puligheddu, Monica , Mollenhauer, Brit , Trenkwalder, Claudia , Sixel‐Döring, Friederike , Biscarini, Francesco , Antelmi, Elena, Heidbreder, Anna , Kulcsárová, Kristína , Mattioli, Pietro , Arnaldi, Dario , Boeve, Bradley F. , Blauwendraat, Cornelis , Postuma, Ronald B. , Gan‐Or, Ziv

Mayo Clinic

No container title available | February 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.05.26345599 | PMID 41674635 Get It

Abstract Isolated/idiopathic rapid-eye-movement (REM)-Sleep Behavior Disorder (iRBD) is characterized by dream enactment behaviors associated with loss of REM atonia. iRBD is in most cases a prodromal synucleinopathy, and emerging evidence suggests associations between RBD and other neurological and psychiatric conditions. In this study, we performed pathway-based polygenic risk score (PRS) and rare variant burden analyses to examine these potential associations. Pathway-specific PRS were constructed from genome-wide association study summary statistics of five neurodegenerative and seven psychiatric traits across 10 biologically relevant pathway categories, including a total of 279 pathways, in 1,573 iRBD cases and 16,022 controls from the International RBD Study Group and UK Biobank. Rare variant burden tests were performed in 1,264 iRBD cases and 2,581 controls. We identified multiple potential pathways indicating shared polygenic risk between RBD and both neurodegenerative and psychiatric disorders. Lewy body diseases and post-traumatic stress disorder had the most shared polygenic risk pathways in neurological and psychiatric disorders, respectively. Two pathways, the serotonin transport pathway and the chaperone-mediated autophagy pathway, showed the strongest association with iRBD, and gene-based rare variants analyses revealed five genes associated with iRBD: GBA1 , PLEKHM1 , LRP2 , P2RX1 , and HAP1. Subsequent analysis of these genes in Parkinson’s disease and dementia with Lewy bodies replicated several associations. Together, these findings provide novel insights into the shared genetic architecture underlying iRBD, neurodegenerative disorders, and psychiatric traits, with implications for early identification and mechanistic understanding.